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INTRODUCTION

O ptic neuritis (ON) is a common neuro-ophthalmologic inflammatory disease that results in persistent vision
impairment in young adults. Idiopathic demyelinating optic neuritis (IDON), the most common clinical type, is strongly associated with multiple sclerosis (MS) [1] . Experimental autoimmune encephalomyelitis (EAE) is a commonly used model for studying of ON and MS [2] . Methylprednisolone pulse therapy has been the mainstay of treatment for the acute phase of ON. Corticosteroids accelerate the recovery of vision; however, they do not improve the visual prognosis [3] . Numerous undesirable side effects are associated with corticosteroids.
One study even indicates that methylprednisolone accelerates neuron apoptosis in the central nervous system [4] . In addition to a wide range of demyelinating lesions in acute and chronic MS and ON, axonal loss and neuronal apoptosis occur and are closely related to irreversible loss of vision [5] .
Therefore, alleviating demyelination and promoting neural protection during the acute inflammatory phase, should be a priority in the clinical treatment. With the serious side effects of corticosteroids and their lack of neuroprotective effect, patients with ON urgently need a novel medication 542 with anti-inflammatory properties, immune regulation, and neuroprotective effects. Gynostemma pentaphyllum makino, a popular herb used in traditional Chinese medicine, has been used in food and tea at length owing to its ability to prevent chronic diseases such as hepatitis, hypertension, and gastritis [6] . Gypenosides, saponin extracts from Gynostemma pentaphyllum, has been shown to provide various bioactivities such as antioxidation, hepatoprotection, antilipidemia and inflammation reduction. The neuroprotective effect of gypenosides has been proven and current research is mainly focused on ischemia-reperfusion injury, Alzheimer's Disease, Parkinson's Disease [7] [8] [9] . However, the protective effect of gypenosides in ON has not been established. In the present study, an in-vivo model was used to evaluate the potential therapeutic effects of gypenosides on functional and histological alterations of experimental autoimmune optic neuritis (EAON).
MATERIALS AND METHODS
Animals Four-week-old female C57BL/6 mice were purchased from the Slaccs-jingda (SLACCS, HUNAN 
Retinal Nerve Fiber Layer Thickness Measurements
Average retinal nerve fiber layer (RNFL) thickness for 360°
around the optic disc was measured by the optical coherence tomography (OCT) (Heidelberg, Germany). Animals were anesthetized by intraperitoneal injection of 1% pentobarbital sodium in 0.1 mL and the pupils were dilated with tropicamide (5 mg/mL). Mice were placed on a platform, and adjusted by another doctor to ensure that incident OCT beam entered through the pupil as well as perpendicular to the cornea. The region of measurement was defined as a circle, about 3.46 mm in diameter (system setting), using the optic disc as the center. 
Histopathologic Evaluation of Optic Nerves
RESULTS
Latency Delay in Visual Evoked
Gypenosides Treatment Reduces Optic Nerve Demyelination
Optic nerve sections from each groups were stained with Lfb ( Figure 3A ) to examine whether gypenosides can protect against demyelination during EAON. We did not find a 
Gypenosides Treatment Reduces Optic Nerve Inflammation
Sections of the optic nerves and retina were stained by HE at 20d p.i. to determine the anti-inflammatory effect of gypenosides. In the retinal section, inflammatory cells were detected in the ganglion cell layer in the model and the gypenosides (15 and 30 mg/kg) group (the arrow points, Figure 5A ). In the EAON model group, a remarkable increased thickness of the inner plexiform layer (IPL) was revealed (the arrowheads points the IPL, Figure 5A ). Significant inflammatory cell infiltration appeared in optic nerves in the model group (the arrow points in Figure 5B ). In the treatment groups, there was less infiltration of inflammatory cells in VEP is a noninvasive tool for investigating the function of the visual system and has been used to study the visual pathway function in models of EAE [10] . In general, VEP latency prolongation in ON may be related to the conduction velocity decreasing in demyelinating lesions. One study has observed that demyelination coincided with VEP latency prolongation [11] .
In the present study, we utilized VEP to measure demyelination of neurological deficit [12] . In addition, the production of a massive reactive oxygen species (ROS) attacks lipids and proteins and exceeds the antioxidant capacity of the body. The central nervous system is prone to damage by lipid peroxidation due to its high oxygen consumption and rich presence of lipid. Experiments show that the body's endogenous active oxygen scavenger is insufficient to protect the central nervous system against ROS-induced damage.
Administration of an exogenous ROS scavenger can reduce blood-brain barrier injury and demyelination in EAON [13] .
Recently, many experiments have confirmed the anti-oxidative effect of gypenosides, including as an anti-inflammatory. As an activator of peroxisome proliferator-activated receptor α (PPAR-α), gypenosides can inhibit the tissue factor activation and over-expression that occur in inflammatory processes mediated by lipopolysaccharides [14] . Gypenosides also reduce lipid peroxidation and DNA damage in low perfusion models in the cerebral cortex and hippocampus of rats [15] . [16] . The subsequent retrograde axonal degeneration causes thinning of the RNFL [17] . [18] . Meanwhile, the accumulation of amyloid protein or metabotropic glutamate in axonal demyelination lesions can also lead to axonal damage [19] . Amyloid precursor protein, a characteristic sign in axonal damage, have been observed at demyelinating lesions [20] . A recent study has found gypenosides attenuates β amyloid-induced inflammation by reducing microglial activation, increasing the levels of iNOS expression, and increasing neurotrophic factor and IL-10 releases [21] . It is possible that in our study gypenosides plays a similar role in EAON. [22] . In other experiments, gypenosides shows a dose-dependent effect in attenuated MMP (+) -induced oxidative damage. The neuroprotective effect of gypenosides may be attributed to increased glutathione content and enhanced activity of glutathione peroxidase and superoxide dismutase in nigral culture [23] [24] . Gypenosides-17, a novel phytoestrogen isolated from Gynostemma pentaphyllum, conferred protection in a cell model of Alzheimer disease through activation of PI3K/Akt and Nrf2/ARE/HO-1pathways
and inactivation of GSK-3β [25] . This experiment provided a novel perspective into the mechanism for the neuroprotective effects of gypenosides.
It is well known that corticosteroids are the main therapy for ON but will not improve the visual outcome. Moreover, they have adverse effects on neuron survival [4] . Therefore, corticosteroids together with an anti-inflammatory and neuroprotective medication, such as gypenosides, may bring a new hope to those patient suffering from ON.
In conclusion, this is the first report to demonstrate the ability 
